Tag Archives: UK

The UK's New "Revolutionary" Medicines Optimization Plan

By Guest Blogger | Published: May 21, 2013
By Leela Barham. The UK’s Royal Pharmaceutical Society has joined forces with a number of other organizations, including the Association of the British Pharmaceutical Industry (ABPI), to issue new guidance on medicines optimization.  Sir Bruce Keogh, Medical Director of NHS England, says it could be revolutionary.
Posted in Europe, Global, Guest Blog, Op-Ed | Also tagged , , , , , | Leave a comment

Measles Outbreak in UK: Why We Need to Maintain a Balance of Communication Power

By Guest Blogger | Published: April 22, 2013
The current UK measles outbreak reminds us that, as far as healthcare communication is concerned, the voice of the people is not necessarily the voice of God, writes Reflector. The localized outbreak of measles in the UK is alarming in more ways than one. There can only be sympathy for the victims of this sudden return [...]
Posted in Europe, Global, Guest Blog, Patient Communication, Technology, healthcare, patient education, social media | Also tagged , | Leave a comment

England's Cancer Drug Fund: An Acid Test for Value Based Pricing

By Guest Blogger | Published: April 12, 2013
By Leela Barham. England’s Cancer Drugs Fund (CDF) could be in its final financial year, after running in full since April 2011.  The fund covers the cost of cancer treatments either when NICE has said ‘no’, or hasn’t yet come to a view.  Companies can’t circumvent NICE though; if a company was invited to submit to [...]
Posted in Europe, Global, Guest Blog, Op-Ed, pricing | Also tagged , , , , | Leave a comment

AstraZeneca's R&D Trimdown, Points to Shift in The Way Big Pharma Invents

By Clark Herman | Published: March 20, 2013
AstraZeneca’s decision to cut 5,050 jobs by 2016 and cease R&D operations at its Alderley Park, UK facility has many wondering where CEO Pascal Soriot plans to take the company. The opening of a new $500 million facility in Cambridge is at once a consolation prize for the UK government’s efforts to placate a skittish [...]
Posted in Biotech, Europe, R&D, Strategy | Also tagged , | Leave a comment

NICE: What the New Compliance Regime Will Mean for Pharma

By Guest Blogger | Published: September 21, 2012
By Martin Smith and Tim Suter. A recent decision by the Department of Health (DoH) to introduce a compliance regime for NICE (National Institute for Health and Clinical Excellence) technology appraisals will open the door to ensuring better implementation by NHS Trusts and Joint Prescribing Groups of NICE guidance. Importantly, the regime will also open new avenues [...]
Posted in Global, Guest Blog, Regulatory | Also tagged , , , | Leave a comment